Biora Therapeutics Inc. [BIOR] is -66.99% lower this YTD. Is it still time to buy?


Biora Therapeutics Inc. [NASDAQ: BIOR] price surged by 9.35 percent to reach at $0.06. The company report on July 7, 2022 that Biora Therapeutics Announces Successful Completion of Second Device Performance Study in Human Subjects for its Targeted Therapeutics Platform.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Study demonstrated device functioned as designed when administered with food, potentially enabling non-fasted administration.

Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today announced topline results from its recently completed study PM-611: Safety and Functionality Assessment of the Drug Delivery System (DDS) Capsule in humans. The study assessed whether the autonomous location functionality of the ingestible devices was impacted by a fed state as compared to a fasted state.

A sum of 3072163 shares traded at recent session while its average daily volume was at 2.78M shares. Biora Therapeutics Inc. shares reached a high of $0.7654 and dropped to a low of $0.64 until finishing in the latest session at $0.69.

The one-year BIOR stock forecast points to a potential upside of 82.75. The average equity rating for BIOR stock is currently 1.50, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Biora Therapeutics Inc. [BIOR]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BIOR shares is $4.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BIOR stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Average True Range (ATR) for Biora Therapeutics Inc. is set at 0.07, with the Price to Sales ratio for BIOR stock in the period of the last 12 months amounting to 106.02.

BIOR Stock Performance Analysis:

Biora Therapeutics Inc. [BIOR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.19. With this latest performance, BIOR shares dropped by -10.76% in over the last four-week period, additionally sinking by -69.34% over the last 6 months – not to mention a drop of -77.67% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BIOR stock in for the last two-week period is set at 48.43, with the RSI for the last a single of trading hit 52.01, and the three-weeks RSI is set at 45.78 for Biora Therapeutics Inc. [BIOR]. The present Moving Average for the last 50 days of trading for this stock 0.7543, while it was recorded at 0.6689 for the last single week of trading, and 1.7041 for the last 200 days.

Insight into Biora Therapeutics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Biora Therapeutics Inc. [BIOR] shares currently have an operating margin of -9449.64 and a Gross Margin at -15.24. Biora Therapeutics Inc.’s Net Margin is presently recorded at -14316.04.

Biora Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.60.

Biora Therapeutics Inc. [BIOR] Insider Position Details

There are presently around $35 million, or 29.80% of BIOR stock, in the hands of institutional investors. The top three institutional holders of BIOR stocks are: ATHYRIUM CAPITAL MANAGEMENT, LP with ownership of 29,855,847, which is approximately 0% of the company’s market cap and around 2.70% of the total institutional ownership; NEUBERGER BERMAN GROUP LLC, holding 6,541,060 shares of the stock with an approximate value of $4.51 million in BIOR stocks shares; and VANGUARD GROUP INC, currently with $3.56 million in BIOR stock with ownership of nearly 7.674% of the company’s market capitalization.

Positions in Biora Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 27 institutional holders increased their position in Biora Therapeutics Inc. [NASDAQ:BIOR] by around 5,489,113 shares. Additionally, 25 investors decreased positions by around 2,906,741 shares, while 18 investors held positions by with 42,638,918 shares. The mentioned changes placed institutional holdings at 51,034,772 shares, according to the latest SEC report filing. BIOR stock had 13 new institutional investments in for a total of 883,338 shares, while 15 institutional investors sold positions of 1,621,654 shares during the same period.